BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Pulse Biosciences (PLSE)Pulse BiosciencesCompany update

Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed 12-month follow-up HAYWARD, Calif. --(BUSINESS WIRE)--Sep. 15, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™

Related news

PLSEPulse Biosciences2026-07-29 11:00 EST

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

PLSEPulse Biosciences2026-07-21 20:05 EST

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

HYPRHyperfine2026-09-15 12:15 EST

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

HYPRHyperfine2026-07-30 12:15 EST

Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care

TMCITreace Medical Concepts2026-09-17 21:16 EST

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

TMCITreace Medical Concepts2026-09-15 21:07 EST

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

AEMDAethlon Medical2026-07-13 12:01 EST

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

SGHTSight Sciences2026-08-04 21:38 EST

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

ICCMIceCure Medical2026-07-27 12:32 EST

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

DCTHDelcath Systems2026-07-09 12:00 EST

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

View all latest news

Pulse Biosciences

Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac...

Recent company news

PLSEPulse Biosciences2026-09-15 11:00 EST

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

PLSEPulse Biosciences2026-09-04 11:00 EST

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PLSEPulse Biosciences2026-08-18 11:00 EST

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

PLSEPulse Biosciences2026-07-30 20:05 EST

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Stock data

Close
50.61 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States